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Abstract
Background: Bortezomib (Velcade®), a dipeptide boronate proteasome inhibitor, is a novel anti-
cancer agent registered for multiple myeloma (MM). It has also shown promising clinical activity in
non-small cell lung cancer (NSCLC). Clinical experience with bortezomib so far indicates that
overall incidence of cardiac failure associated with bortezomib therapy remains incidental.
Nevertheless, acute development or exacerbation of congestive cardiac failure has been associated
with bortezomib treatment.
Case presentation: We present here a case of severe, but reversible, congestive cardiac failure
in a lung cancer patient who had no prior cardiac history, after receiving an experimental treatment
of bortezomib combined with chemotherapy. Elevated levels of N-terminal pro-B-type natriuretic
peptide (NT-proBNP), as retrospectively measured in archived serum samples, were suggestive of
pre-existent (sub-clinical) left ventricular dysfunction.
Conclusion:  Based on literature, we hypothesize that baseline presence of sub clinical
cardiomyopathy, characterized by a dysregulation of the ubiquitin-proteasome system, could have
predisposed this patient for a cardiac side effect induced by systemic proteasome inhibition.
Patients with heart disease or risk factors for it should be closely monitored when being submitted 
to treatment with proteasome inhibition therapy such as bortezomib. Caution is therefore 
warranted in lung cancer patients who often present with cardiac comorbidities.
Background
The proteasome is a large protein complex with ATP-
dependent proteolytic activity. In the evolutionarily
highly conserved ubiquitin-proteasome pathway (UPP), a
protein is "tagged" for degradation by the proteasome,
when it is labeled with a chain of multiple ubiquitin mol-
ecules [1]. Bortezomib is a reversible inhibitor of the pro-
teasome. Inhibition results in the accumulation of poly-
ubiquitinated proteins involved in a plethora of signaling
pathways. Among other effects, this can trigger apoptosis,
with a relative selectivity in cytotoxicity for malignant as
opposed to normal cells [2].
Bortezomib, currently registered for multiple myeloma,
showed some clinical activity as monotherapy in unse-
lected non-small cell lung cancer (NSCLC) patients [3,4].
However, there is a strong preclinical rationale to investi-
gate combination treatments of bortezomib and chemo-
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therapy in solid tumors, including NSCLC. The patient we
report here was included in a dose-finding study of borte-
zomib combined with cisplatin-gemcitabine chemother-
apy in first-line treatment of patients with advanced solid
tumors [5].
Case presentation
A 53-year-old male patient with stage IIIB squamous cell
carcinoma of the lung, not invading the great vessels or
heart structures, was treated with bortezomib combined
with cisplatin-gemcitabine. The patient completed four 3-
week cycles of bortezomib 1.0 mg/m2 on days 1 and 8, cis-
platin 70 mg/m2 on day 1, gemcitabine 1000 mg/m2 on
days 1 and 8. An impressive radiological partial response
(PR) was observed after 2 cycles of therapy, and confirmed
after 4 cycles, according to the Response Evaluation Crite-
ria for Solid Tumors (RECIST) criteria [6]. The longest
diameter of the primary tumor in the left lower lobe had
decreased from 85 to 35 millimeters (minus 59%).
However, from cycle 2 onwards, the patient had com-
plained of increasing fatigue, orthopnea, and dyspnea on
exertion. This was most evident during the first days of
each cycle, following bortezomib, gemcitabine and cispl-
atin administration, including cisplatin-hydration (6 liter
of fluids in 27 hours). Though he had been a heavy
smoker (36 pack years) and had a history of COPD he did
not have a documented or symptomatic prior cardiac his-
tory.
Because of the good anti-tumor response, treatment was
continued. Upon admission for start of cycle 5, ausculta-
tion of the heart had revealed no abnormalities. Pulmo-
nary auscultation was unchanged compared to prior
examinations with a diffuse prolonged expiration and
occasional rales but no crepitations. Central venous pres-
sure as determined by neck vein distension was not ele-
vated and there was no peripheral edema. During the
night he received a transfusion of two packed cells for ane-
mia (Hb 5.4 mmol/l).
Upon completion of cisplatin prehydration (1 liter of flu-
ids), the patient became progressively dyspnoic. He did
not experience any chest pain. An ECG did not show signs
of ischemia. Chest-x-ray showed an increased heart-chest
ratio of 0.57 compared to baseline 0.50, and mild signs of
redistribution. His dyspnea improved remarkably upon
administration of furosemide.
All chemotherapy was discontinued and he was released
the next day in a clinically stable condition, though
fatigue and dyspnea upon exertion had considerably
worsened compared to baseline. An echocardiography
performed the following week showed dilatation of the
left ventricle and atrium. Ejection fraction (EF) was esti-
mated to be 10–15%. A cardiac 99mTc-MIBI scan per-
formed two weeks later showed diffuse hypokinesis and
fixed perfusion defects in the apex and inferior wall. Treat-
ment was initiated with atenolol, lisinopril and acenocou-
marol. The first three months of follow-up did not show
clinical improvement, and an echocardiography per-
formed at that time estimated EF still at 20–30%. For
these reasons no consolidation radiotherapy to the pri-
mary tumor was given. Fortunately, at six months of fol-
low-up his condition had improved to New York Heart
Association (NYHA) class I-II. At that time coronary angi-
ography was performed which did not show significant
abnormalities aside from calcification of the left anterior
descending artery. At eight months of follow-up, a Multi-
ple Gate Acquisition (MUGA)-scan showed a restoration
of the EF to 45%. Unfortunately, at this time progression
of his lung tumor was evident and second-line therapy
was started shortly after.
As we did not have a pre-treatment EF value of this
patient, N-terminal pro-B-type natriuretic peptide (NT-
proBNP) was determined in a pre-treatment serum sam-
ple as a surrogate marker for baseline left ventricular func-
tion (LVF). Figure 1 shows that already at baseline NT-
proBNP was considerably elevated at 1389 ng/L, corre-
sponding to a level generally found in NYHA Class II-III
patients [7]. Analyzing two additional serum samples
showed an increase to 2569 ng/L post cycle 2 (six weeks
on treatment) and to 5177 ng/L at end-of-treatment (post
cycle 4, twelve weeks on treatment) indicating a progres-
sive worsening of the LVF during treatment. Troponin as
well as CK-MB levels were not elevated in any of the sam-
ples tested. As a control, NT-proBNP at baseline and end-
of-treatment was determined in two other patients partic-
ipating in the same clinical trial and who had similar
exposure to bortezomib and chemotherapy. NT-proBNP
remained within normal limits in these two patients. Also
LVEF was determined by MUGA-scan at baseline and at
end-of-treatment in these two patients and found not to
have decreased during treatment. A baseline and end-of-
treatment MUGA-scan had been incorporated into the
trial design after occurrence of the case as described above.
In the case patient, at eleven months of follow-up and car-
diac medication, NT-proBNP had decreased to a level
within normal limits (110 ng/L).
We attribute the severe reduction of the LVEF in this case
primarily to the drug treatment with bortezomib, gemcit-
abine and cisplatin. Main arguments are its reversibility
and the negative findings of coronary angiography and
additional investigations. The straining cisplatin-hydra-
tion was probably also an attributing factor, though
unlikely to be the primary cause, as one would generally
not expect such a slow recovery after a mere overload
induced cardiac failure.BMC Cancer 2006, 6:129 http://www.biomedcentral.com/1471-2407/6/129
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Cisplatin and gemcitabine have not been clearly associ-
ated with cardiac failure, though cisplatin has been occa-
sionally associated with acute as well as late arterial
occlusive events such as myocardial infarction and cere-
brovascular thrombotic events. Cisplatin-induced altera-
tion of platelet aggregation as well as vascular damage are
possibly involved [8-10]. A study evaluating LVEF of 31
NSCLC patients immediately before and 12 weeks after
finishing first-line cisplatin-gemcitabine chemotherapy
did not demonstrate a significant decrease in LVEF [11].
Clinical experience with bortezomib so far indicates that
the incidence of cardiac failure or other cardiovascular
effects remains incidental. Nevertheless, the US package
insert states that acute development or exacerbation of
congestive heart failure, and/or new onset of decreased
left ventricular ejection fraction has been reported [12]. It
must be noted that the package insert covers adverse
events observed with bortezomib monotherapy only,
which does not require pre- and/or post-hydration and
represents a minimal fluid load. The largest study con-
ducted so far with bortezomib was the APEX study, a 669
patient phase 3 study, comparing bortezomib with high-
dose dexamethasone in heavily pretreated patients with
relapsed multiple myeloma. This study did not show a
negative impact of bortezomib on the incidence of con-
gestive heart failure, which was comparable in both arms
at 2 percent [13].
There is evidence from literature that activation of the
ubiquitin-proteasome system (UPS) occurs in chronic
conditions of left ventricular hypertrophy and (dilated)
cardiomyopathy. Increased expression of genes coding for
ubiquitin-proteasome pathway was demonstrated in a rat
cardiac hypertrophy model [14]. Furthermore, in dilated
cardiomyopathy (DCM) patients, increased expression of
regulatory proteins of the UPS was demonstrated by func-
tional proteomics in heart tissue specimens. Activation of
the UPS, leading to an altered protein expression in car-
diac muscle cells, has been proposed to be an adaptive
mechanism for maintaining a normal stroke volume [15].
Interestingly, susceptibility for cardiovascular disease has
been ascribed to age-related decrease in proteasome activ-
ity, impairing the the ability of myocytes to mount an
appropriate response to stress [16].
In this patient, baseline left ventricular dysfunction was
shown by retrospective analysis of serum NT-proBNP, a
peptide that is secreted by cardiac myocytes upon ven-
tricular distension and overload. Elevated levels are
related to (acute) congestive heart failure and increased
long-term mortality [17]. NT-proBNP has been shown to
remain stable in serum samples stored over a prolonged
period of time, which allowed retrospectively analysis in
remaining serum samples [18].
Conclusion
We hypothesize that baseline presence of sub clinical car-
diomyopathy, characterized by an adaptive, cytoprotec-
tive activation of the UPS, could have predisposed this
patient for a cardiac side effect induced by systemic pro-
teasome inhibition.
We recommended that patients with heart disease or risk
factors for it should be closely monitored when treated
with systemic proteasome inhibition therapy. Caution is
therefore warranted in lung cancer patients who often
present with cardiac comorbidities. Episodic measure-
ments of NT-proBNP may be of use in this regard, how-
ever this needs to be validated in further studies.
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Serum levels of NT-proBNP in case report patient," case",  and two control patients "control 1"and "control 2" Figure 1
Serum levels of NT-proBNP in case report patient," case", 
and two control patients "control 1"and "control 2". NT-
proBNP was measured in case patient at baseline (1389 ng/
L), post cycle 2 (2569 ng/L), end-of-treatment (5177 ng/L) 
and at follow-up (110 ng/L), 10 months after end of treat-
ment. In control patients NT-proBNP was measured at base-
line and end-of-treatment only. Baseline NT-proBNP values 
for control patients 1 and 2 were 117 ng/L and 31 ng/L, end-
of-treatment values 31 ng/L and 142 ng/ml respectively. Insti-
tutional upper limit of normal is 179 ng/L.
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